Filtered By:
Specialty: Internal Medicine
Source: Annals of Internal Medicine
Drug: Clopidogrel
This page shows you your search results in order of date.
Order by Relevance | Date
Total 21 results found since Jan 2013.
In CV disease, clopidogrel reduces nonfatal MI and MACE vs. aspirin but not stroke or mortality
Ann Intern Med. 2022 Dec 6. doi: 10.7326/J22-0094. Online ahead of print.NO ABSTRACTPMID:36469913 | DOI:10.7326/J22-0094
Source: Annals of Internal Medicine - December 5, 2022 Category: Internal Medicine Authors: Akshay Goel Aaqib H Malik Source Type: research
Ticagrelor-Aspirin Versus Clopidogrel-Aspirin Among < em > CYP2C19 < /em > Loss-of-Function Carriers With Minor Stroke or Transient Ischemic Attack in Relation to Renal Function: A Post Hoc Analysis of the CHANCE-2 Trial
CONCLUSION: Patients with normal, rather than impaired, renal function received greater benefit from ticagrelor-aspirin versus clopidogrel-aspirin.PRIMARY FUNDING SOURCE: Ministry of Science and Technology of the People's Republic of China.PMID:36315949 | DOI:10.7326/M22-1667
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Anxin Wang Xuewei Xie Xue Tian S Claiborne Johnston Hao Li Philip M Bath Yingting Zuo Jing Jing Jinxi Lin Yilong Wang Xingquan Zhao Zixiao Li Yong Jiang Liping Liu Xia Meng Yongjun Wang Source Type: research
In patients with stroke or TIA and CYP2C19 loss-of-function alleles, ticagrelor vs. clopidogrel reduced 90-d stroke
Ann Intern Med. 2022 Mar 1. doi: 10.7326/J22-0008. Online ahead of print.ABSTRACTWang Y, Meng X, Wang A, et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N Engl J Med. 2021;385:2520-30. 34708996.PMID:35226525 | DOI:10.7326/J22-0008
Source: Annals of Internal Medicine - February 28, 2022 Category: Internal Medicine Authors: Raed A Joundi Source Type: research
